Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03296371 · ClinicalTrials.gov registry record
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma
A clinical trial of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma, sponsored by Children's Oncology Group.
- Active
- Registry status
- 900
- Enrollment target
- 1
- Study location
NCT03296371: Active study of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma, sponsored by Children's Oncology Group.
NCT03296371 is a study of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 900 participants, above the 216-participant average among 3 other Embryonal Rhabdomyosarcoma trials with a reported enrollment target (317% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03296371, a study of Embryonal Rhabdomyosarcoma and Alveolar Rhabdomyosarcoma, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.
Primary Outcome
Will analyze de novo single-nucleotide variants (SNVs), copy-number variants (CNVs), and insertions/deletions (INDELs) obtained through next-generation exome sequencing of rhabdomyosarcoma (RMS) case-parent trios.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
Study Locations (1)
Pennsylvania
- Childrens Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2026-12-31 |
What the registry record for NCT03296371 still lists
NCT03296371 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 216-participant average among 3 other Embryonal Rhabdomyosarcoma trials with a reported enrollment target (317% higher).
The record links to 2 conditions, with Embryonal Rhabdomyosarcoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT03296371 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03296371 about?
NCT03296371 is a clinical study titled "Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma". This research trial studies genetic mutations in saliva or buccal mucosa samples from patients with embryonal or alveolar rhabdomyosarcoma. Identifying gene mutations may help doctors learn about the prognosis of patients with embryonal or alveolar rhabdomyosarcoma.
What is the current status of trial NCT03296371?
This trial is currently active not recruiting. The enrollment target is 900 participants. The study started on 2017-10-23. Estimated completion is 2026-12-31.
What conditions does trial NCT03296371 study?
This clinical trial studies the following conditions: Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma.
What interventions are being tested in trial NCT03296371?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT03296371?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03296371 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Embryonal Rhabdomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
RECRUITING · Phase 3
-
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI